Biogen · 4 hours ago
Intern, Process Biochemistry
Biogen is a mid-sized biotechnology company committed to delivering life-changing medicines. The role involves supporting the characterization of downstream unit operations, particularly focusing on TFF operations and the associated pH and excipient shifts.
BiotechnologyHealth CareNeuroscienceTherapeutics
Responsibilities
Perform a literature review on current understanding of pH and excipient shifts during TFF operations and models used to characterize these shifts
Summarize internal data regarding ph and excipient concentration shifts in characterized TFF operations
Perform TFF experiments to support mechanistic or empirical models
Qualification
Required
Familiarity with drug substance downstream unit operations
Experience performing literature reviews
Excellent verbal and written communication skills, time management and organizational skills
Legal authorization to work in the U.S
At least 18 years of age prior to the scheduled start date
Currently enrolled in an accredited community college, college, university or skills program/apprenticeship
Exceptional undergraduate student who has completed at least three years of program, or a first year Master's program, with 0-2+ years' experience desired
Desired majors include: Bio/Chemical Engineering, Biomanufacturing or related field
Preferred
Familiarity with mechanistic or empirical modeling is desirable
Benefits
Company paid holidays
Commuter benefits
Employee Resource Groups participation
80 hours of sick time per calendar year
Company
Biogen
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
H1B Sponsorship
Biogen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (100)
2024 (93)
2023 (101)
2022 (134)
2021 (104)
2020 (114)
Funding
Current Stage
Public CompanyTotal Funding
$1.5BKey Investors
JP Morgan
2023-08-28Post Ipo Debt· $1.5B
1991-09-27IPO
Leadership Team
Recent News
Company data provided by crunchbase